Postradioiodine Treatment Whole-Body Scan in the Era of 18-Fluorodeoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with Elevated Serum Thyroglobulin Levels
Abstract
Background: Patients with differentiated thyroid cancer (DTC) who have a suspicious recurrent or persistent disease based on an elevated serum thyroglobulin (Tg) or Tg antibodies (TgAb) are usually referred for empiric radioiodine (131I) administration to localize and treat the disease. The aim of this retrospective monocentric study was to assess the sensitivity of postempiric 131I whole-body scan (WBS) compared to 18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in such patients who had an initial normal postablation WBS.
Methods: Among 47 consecutive patients with DTC who had a normal postablation WBS and were referred for empiric 131I administration, 34 patients (12M, 22F; mean age 53 years) underwent FDG PET/CT and form the basis of this report: 23 patients had persistently elevated serum Tg levels, 10 had elevated Tg levels observed during follow-up after they initially became under 1 ng/mL, and 1 had appearance of TgAb during follow-up. Postempiric 131I WBS and FDG PET/CT were analyzed by independent readers.
Results: A total of 75 lesions were found in 23 patients, distributed in 36 organs. Lesions were located in the neck (30), lungs (28), mediastinum (11), and bones (6). The sensitivities for the detection of individual lesions and for the diagnosis of metastatic organs were 88% and 97% for PET/CT and 16% and 22% for WBS, respectively (p<0.01). PET/CT was abnormal in 22 patients, among which 5 also had an abnormal postempiric 131I WBS. There was only one patient with an abnormal postempiric 131I WBS and a normal FDG PET/CT. This patient underwent two further 131I administrations, with the last WBS being normal and the last stimulated Tg level being undetectable. Other patients were either treated with surgery, or classified as radioactive iodine refractory and treated with levothyroxine suppressive therapy or tyrosine kinase inhibitors.
Conclusion: In patients with suspicious recurrence based on the Tg level after a normal postablation WBS, FDG PET/CT is the preferred scintigraphic method to localize disease rather than postempiric 131I WBS. Empiric 131I administration may be used only in patients who do not have a significant FDG uptake.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Cooper DSDoherty GMHaugen BRKloos RTLee SLMandel SJMazzaferri ELMcIver BPacini FSchlumberger MSherman SISteward DLTuttle RM2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid191167-1214. 1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214.
2.
Galligan JPWinship Jvan Doorn TMortimer RH1982. A comparison of serum thyroglobulin measurements and whole body 131I scanning in the management of treated differentiated thyroid carcinomaAust NZ J Med12248-254. 2. Galligan JP, Winship J, van Doorn T, Mortimer RH 1982 A comparison of serum thyroglobulin measurements and whole body 131I scanning in the management of treated differentiated thyroid carcinoma. Aust NZ J Med 12:248–254.
3.
Schlumberger MTubiana MDe Vathaire FHill CGardet PTravagli JPFragu PLumbroso JCaillou BParmentier C1986. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinomaJ Clin Endocrinol Metab63960-967. 3. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960–967.
4.
Pacini FLippi FFormica NElisei RAnelli SCeccarelli CPinchera A1987. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levelsJ Nucl Med281888-1891. 4. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A 1987 Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888–1891.
5.
Leboulleux SSchroeder PRSchlumberger MLadenson PW2007. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancersNat Clin Pract Endocrinol Metab3112-121. 5. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW 2007 The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 3:112–121.
6.
Dong MJLiu ZFZhao KRuan LXWang GLYang SYSun FLuo XG2009. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysisNucl Med Commun30639-650. 6. Dong MJ, Liu ZF, Zhao K, Ruan LX, Wang GL, Yang SY, Sun F, Luo XG 2009 Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 30:639–650.
7.
Wang WLarson SMTuttle RMKalaigian HKolbert KSonenberg MRobbins RJ2001. Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodineThyroid111169-1175. 7. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ 2001 Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11:1169–1175.
8.
Robbins RJWan QGrewal RKReibke RGonen MStrauss HWTuttle RMDrucker WLarson SM2006. Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanningJ Clin Endocrinol Metab91498-505. 8. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning. J Clin Endocrinol Metab 91:498–505.
9.
Deandreis DAl Ghuzlan ALeboulleux SLacroix LGarsi JPTalbot MLumbroso JBaudin ECaillou BBidart JMSchlumberger M2011. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?Endocr Relat Cancer18159-169. 9. Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, Lumbroso J, Baudin E, Caillou B, Bidart JM, Schlumberger M 2011 Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 18:159–169.
10.
Kim WGRyu JSKim EYLee JHBaek JHYoon JHHong SJKim ESKim TYKim WBShong YK2010. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scanJ Clin Endocrinol Metab951169-1173. 10. Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB, Shong YK 2010 Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab 95:1169–1173.
11.
Leboulleux SGirard ERose MTravagli JPSabbah NCaillou BHartl DMLassau NBaudin ESchlumberger M2007. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancerJ Clin Endocrinol Metab923590-3594. 11. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlumberger M 2007 Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 92:3590–3594.
12.
AJCC 2010 Thyroid glandSobin LHGospodarowicz MWittekind CUICC TNM Classification of Malignant Tumors7thBlackwell Publishing Ltd.Oxford, United Kingdom58-62. 12. AJCC 2010 Thyroid gland. In: Sobin LH, Gospodarowicz M, Wittekind C (eds) UICC TNM Classification of Malignant Tumors, 7th edition. Blackwell Publishing Ltd., Oxford, United Kingdom, pp 58–62.
13.
Mazzaferri ELRobbins RJSpencer CABraverman LEPacini FWartofsky LHaugen BRSherman SICooper DSBraunstein GDLee SDavies TFArafah BMLadenson PWPinchera A2003. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinomaJ Clin Endocrinol Metab881433-1441. 13. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433–1441.
14.
Baudin EDo Cao CCailleux AFLeboulleux STravagli JPSchlumberger M2003. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patientsJ Clin Endocrinol Metab881107-1111. 14. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88:1107–1111.
15.
Tuttle RMTala HShah JLeboeuf RGhossein RGonen MBrokhin MOmry GFagin JAShaha A2010. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging systemThyroid201341-1349. 15. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349.
16.
Brassard MBorget IEdet-Sanson AGiraudet ALMundler OToubeau MBonichon FBorson-Chazot FLeenhardt LSchvartz CDejax CBrenot-Rossi IToubert METorlontano MBenhamou ESchlumberger M2011. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patientsJ Clin Endocrinol Metab961352-1359. 16. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96:1352–1359.
17.
Pacini FMolinaro ECastagna MGAgate LElisei RCeccarelli CLippi FTaddei DGrasso LPinchera A2003. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinomaJ Clin Endocrinol Metab883668-3673. 17. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668–3673.
18.
Torlontano MAttard MCrocetti UTumino SBruno RCostante GD'Azzo GMeringolo DFerretti ESacco RArturi FFiletti S2004. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastasesJ Clin Endocrinol Metab893402-3407. 18. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzo G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S 2004 Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402–3407.
19.
Rivera MGhossein RASchoder HGomez DLarson SMTuttle RM2008. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinomaCancer11348-56. 19. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM 2008 Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113:48–56.
20.
Aide NHeutte NRame JPRousseau ELoiseau CHenry-Amar MBardet S2009. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancerJ Clin Endocrinol Metab942075-2084. 20. Aide N, Heutte N, Rame JP, Rousseau E, Loiseau C, Henry-Amar M, Bardet S 2009 Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. J Clin Endocrinol Metab 94:2075–2084.
21.
Blum MTiu SChu MGoel SFriedman K2011. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patientsThyroid211235-1247. 21. Blum M, Tiu S, Chu M, Goel S, Friedman K 2011 I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients. Thyroid 21:1235–1247.
22.
Leboulleux SSchroeder PRBusaidy NLAuperin ACorone CJacene HAEwertz MEBournaud CWahl RLSherman SILadenson PWSchlumberger M2009. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancerJ Clin Endocrinol Metab941310-1316. 22. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M 2009 Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94:1310–1316.
23.
Kim MHO JHKo SHBae JSLim DJKim SHBaek KHLee JMKang MICha BYLee KW2012. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapyThyroid22157-164. 23. Kim MH, O JH, Ko SH, Bae JS, Lim DJ, Kim SH, Baek KH, Lee JM, Kang MI, Cha BY, Lee KW 2012 Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy. Thyroid 22:157–164.
24.
Durante CHaddy NBaudin ELeboulleux SHartl DTravagli JPCaillou BRicard MLumbroso JDDe Vathaire FSchlumberger M2006. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapyJ Clin Endocrinol Metab982892-2899. 24. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 98:2892–2899.
25.
Jeong HSBaek CHSon YIChoi JYKim HJKo YHChung JHBaek HJ2006. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CTClin Endocrinol (Oxf)65402-407. 25. Jeong HS, Baek CH, Son YI, Choi JY, Kim HJ, Ko YH, Chung JH, Baek HJ 2006 Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 65:402–407.
26.
Grant CSThompson GBFarley DRRichards MLMullan BPHay ID2008. The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinomaWorld J Surg32708-715. 26. Grant CS, Thompson GB, Farley DR, Richards ML, Mullan BP, Hay ID 2008 The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma. World J Surg 32:708–715.
27.
Allen-Auerbach MYeom KPark JPhelps MCzernin J2006. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancerJ Nucl Med47298-301. 27. Allen-Auerbach M, Yeom K, Park J, Phelps M, Czernin J 2006 Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med 47:298–301.
28.
Schlumberger MSherman SI2009. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advancesThyroid191393-1400. 28. Schlumberger M, Sherman SI 2009 Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 19:1393–1400.
Information & Authors
Information
Published In
Copyright
Copyright 2012, Mary Ann Liebert, Inc.
History
Published in print: August 2012
Published online: 1 August 2012
Topics
Authors
Disclosure Statement
The authors declare that no competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.